Pharmaceuticals News and Research

RSS

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

15 Sep 2011

China Botanic third-quarter net sales increase 33.6% to $12.4 million

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines in China, today announced financial results for the three months ended July 31, 2011.

15 Sep 2011

Eli Lilly announces $30M, five-year commitment to fight NCDs in developing countries

U.S.-based pharmaceutical firm Eli Lilly and Company on Tuesday announced it will spend $30 million over five years to fight the rising burden of non-communicable diseases (NCDs) in developing nations, the Indianapolis Star reports.

15 Sep 2011

Roche, Uppsala BIO partner for new open innovation program

Swedish life science initiative Uppsala BIO has formed a strategic partnering agreement with Roche, the world leading pharmaceuticals and diagnostics company, for Uppsala BIO's open innovation program, BIO-X.

15 Sep 2011

UIC researchers to conduct study on televised drug commercials

Do pharmaceutical ads educate patients and improve health -- or merely spur drug sales? Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy will conduct the first comprehensive study of televised drug commercials using Nielsen Media Research and health care utilization data.

15 Sep 2011

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Alexion Pharmaceuticals, Inc. today announced that the Company's study of eculizumab in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

15 Sep 2011

Viewpoints: Shredding Bachmann's vaccine argument; 'super' or 'stupor' committee; Bennet on outmoded drug safety rules

Vaccines were the biggest losers in Monday's GOP presidential candidate's debate, specifically those that are intended to prevent cervical cancer. The main route of HPV infection is sex. That's why you need to vaccinate girls before they become sexually active. The vaccines are exceedingly safe, studies show. There have been very few reports of serious problems from them, none proven. It is simply a lie to say they can cause retardation.

15 Sep 2011

P3 survey: 44% of U.S. patients receive inadequate relief of moderate-to-severe acute pain

A new survey shows almost half (44%) of U.S. patients in outpatient settings received potentially inadequate relief of moderate-to-severe acute pain.

15 Sep 2011

Debt panel sets to work amidst challenging economic picture

As the CBO director spoke at the panel's opening act and provided a bleak impression of the economic forces the 12 members will confront, Republicans and Democrats on the 'super committee' appear to be toeing the usual party lines, with GOP members focusing on entitlement programs and government health care spending, and Democrats pressing for higher tax revenue.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Lucentis receives Health Canada approval to treat vision loss from DME

Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.

14 Sep 2011

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

14 Sep 2011

First Edition: September 14, 2011

Today's early morning highlights from the major news organizations, including lots of talk about the 'super committee' and about the new census numbers regarding the uninsured as well as the second-day analysis regarding some of the controversial comments made during Monday night's GOP presidential primary debate.

14 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

Reminder packaging improves adherence to long-term hypertension medications

People with chronic illnesses are more likely to take long-term medications according to doctors' instructions if the packaging includes a reminder system, according to a new review of evidence.

14 Sep 2011

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

Consuming the soy germ-based compound Natural S-equol and the supplement SE5-OH containing Natural S-equol did not increase the risk of estrogen-sensitive breast cancer, according to a study in the September issue of the peer-reviewed journal Food and Chemical Toxicology.

14 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

Researchers at South Korean lab make advance in fight against neglected tropical diseases

VOA News reports on a scientific breakthrough, which researchers call a "game changer" for developing new drugs, developed at Institut Pasteur Korea [IPK], a South Korean branch of the 124-year-old French research institute that is developing new drugs to combat diseases mainly affecting developing countries, including neglected tropical diseases.

14 Sep 2011

Pharmaceuticals News and Research

KAI enters KAI-4169 development and commercialization agreement with Ono

Cempra's solithromycin demonstrates efficacy comparable to levofloxacin for CABP treatment

China Botanic third-quarter net sales increase 33.6% to $12.4 million

Eli Lilly announces $30M, five-year commitment to fight NCDs in developing countries

Roche, Uppsala BIO partner for new open innovation program

UIC researchers to conduct study on televised drug commercials

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Viewpoints: Shredding Bachmann's vaccine argument; 'super' or 'stupor' committee; Bennet on outmoded drug safety rules

P3 survey: 44% of U.S. patients receive inadequate relief of moderate-to-severe acute pain

Debt panel sets to work amidst challenging economic picture

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Lucentis receives Health Canada approval to treat vision loss from DME

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

First Edition: September 14, 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Reminder packaging improves adherence to long-term hypertension medications

Natural S-equol supplement does not increase risk of estrogen-sensitive breast cancer

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Researchers at South Korean lab make advance in fight against neglected tropical diseases

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence